Christoph Hanefeld

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study

Friedrich Schulze, Henrike Lenzen, Christoph Hanefeld et al. · American Heart Journal · 2006 · 182 citations

Adma Concentration, Cardiovascular Epidemiology, Cardiovascular Disease +11

Basic life support skills of high school students before and after cardiopulmonary resuscitation training: a longitudinal investigation

Theresa M Meissner, Cordula Kloppe, Christoph Hanefeld · Scandinavian Journal of Trauma Resuscitation and Emergency Medicine · 2012 · 94 citations · Full text

Risk factors and myocardial infarction in patients with obstructive sleep apnea: impact of β2-adrenergic receptor polymorphisms

Nina K. Bartels, Jan Börgel, Stefan Wieczorek et al. · BMC Medicine · 2007 · 84 citations · Full text